Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (NCT03393884)
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
Who can join: Review the eligibility criteria below.
Location: University of Alabama Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- University of Alabama Birmingham — Birmingham, Alabama
- Mitchell Cancer Institute (University of South Alabama) — Mobile, Alabama
- Gynecologic Oncology Associates (Hoag Hospital) — Newport Beach, California
- Innovative Clinical Research — Whittier, California
- Advent Health — Orlando, Florida
- Women's Care Florida — St. Petersburg, Florida
- Massachusetts General Hospital — Boston, Massachusetts
- Washington University School of Medicine in St. Louis — St Louis, Missouri
- MD Anderson at Cooper — Camden, New Jersey
- Hackensack University Medical Center — Hackensack, New Jersey
- Monter Cancer Center — Lake Success, New York
- NYU Langone, Long Island — Mineola, New York
- NYU Langone — New York, New York
- Stephenson Cancer Center - Oklahoma University — Oklahoma City, Oklahoma
- Providence Cancer Institute — Portland, Oregon
- Sanford Health — Sioux Falls, South Dakota
- Chattanooga Women's Health — Chattanooga, Tennessee
- The West Clinic — Germantown, Tennessee
- Providence Health Care — Spokane, Washington
- Medical College of Wisconsin — Milwaukee, Wisconsin
- CHUM — Montreal,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Epithelial Ovarian Cancer
- A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy — Phoenix, Arizona
- Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian — Chapel Hill, North Carolina
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) — Glendale, California
- T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors — Pittsburgh, Pennsylvania
- EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma — Seattle, Washington
Explore by condition: All Epithelial Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.